Eli Lilly | Операционный Доход



Operating Profit Изменить Дата
AbbVie USD -1490000000 5.32B 2024-12
Abbott USD 1.91B 41M 2024-12
ALKERMES USD 162.69M 57.93M 2024-12
Amgen USD 2.31B 182M 2024-12
AstraZeneca USD 2.04B 731M 2024-12
Baxter International USD -435000000 590M 2024-12
Biogen USD 441.4M 24.4M 2024-12
Bristol-Myers Squibb USD 793M 1.39B 2024-12
Drreddys Laboratories INR 18.72B 1.17B 2024-12
Eli Lilly USD 5.15B 3.62B 2024-12
Gilead Sciences USD 2.45B 1.56B 2024-12
GlaxoSmithKline GBP 696M 507M 2024-12
Glaxosmithkline GBP 702M 513M 2024-12
Indivior 94M 226M 2024-09
J&J USD 3.89B 549M 2024-12
Medtronic USD 1.65B 51M 2025-01
Merck USD 4.3B 369M 2024-12
Neurocrine Biosciences USD 142M 41.8M 2024-12
Novartis USD 2.28B 1.34B 2024-12
Novartis USD 3.4B 193M 2024-12
Novo Nordisk 33.82B 7.89B 2024-09
Perrigo USD 112.7M 37.4M 2024-12
Pfizer USD -409000000 5.57B 2024-12
Prestige Brands USD 91.96M 7.62M 2024-12
Regeneron Pharmaceuticals USD 990.2M 189.3M 2024-12
Roche Holding CHF 4.39B 1.04B 2024-12
Sanofi EUR 4.09B 1.81B 2024-09
Sanofi EUR 3.64B 1.35B 2024-09
United Therapeutics USD 357.7M 14.6M 2024-12
Zoetis USD 732M 142M 2024-12



Eli Lilly Операционный Доход - Текущие значения, предыдущие значения, прогнозы, графики и экономический календарь - Mar 2025.